Aravax: is an early stages of creating the first safe and rapidly effective treatment for peanut allergy

The MRCF benefits from the membership of leading medical research institutes and affiliated hospitals from Victoria, New South Wales, Western Australia, Queensland and South Australia. Each Member Institute is represented on the Investment Review Committee (individually or as a group nominee) and contributes to the peer review of investment proposals.

Aravax’s mission is to revolutionise the lives of those with peanut allergy by removing the risk of life-threatening reactions to peanuts.

Aravax is a clinical-stage biotechnology company developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment.

www.aravax.com.au